Venture Capital Journal’s September cover story spotlights bioconvergence, and MIG Capital. Dr. Fei Tian outlines MIG’s investment approach in this space and introduces some of the MIG portfolio companies driving it.

In his guest article for GoingPublic, Matthias Guth explains why Europe plays a key role in interventional cardiology, and how MIG portfolio company CoreMedic is part of this development

In a three-part-interview, MIG Capital’s Dr. Fei Tian explains why China’s biotech rise is changing the rules of global innovation – and what Europe must learn from it.

Several media outlets are reporting on MIG Capital’s initial investment in Tibeay.

Multiple media outlets have covered MIG Capital’s press release on its 2025 business performance.

Several German media outlets, including “Manager Magazin,” are reporting on the IPO plans of MIG’s portfolio company IQM.